Deals in Depth: January 2009
Executive Summary
January 2009 dealmaking highlights: Big Pharma consolidation is back in the news as one of the largest mega-mergers in history took place in January with Pfizer's acquisition of Wyeth for $67bn. Abbott topped the list on the device side, leaping into the vision care field with its $2.8bn purchase of Advanced Medical Optics. Meanwhile financing--mainly from private placements--for both the drug and device industries was up from the previous month, and notably pharma showed a 4x increase in private investor funding.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.